Docoh
Loading...

DVA DaVita

DaVita Inc. is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2020, DaVita served 204,200 patients at 2,816 outpatient dialysis centers in the United States. The company also operated 321 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.

Company profile

Ticker
DVA
Exchange
Website
CEO
Javier Rodriguez
Employees
Incorporated
Location
Fiscal year end
Former names
DAVITA HEALTHCARE PARTNERS INC., DAVITA INC, TOTAL RENAL CARE HOLDINGS INC
SEC CIK
IRS number
510354549

DVA stock data

(
)

Calendar

29 Apr 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from DaVita earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.06B 1.06B 1.06B 1.06B 1.06B 1.06B
Cash burn (monthly) (positive/no burn) 35.62M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 145.55M n/a n/a n/a n/a
Cash remaining n/a 915.49M n/a n/a n/a n/a
Runway (months of cash) n/a 25.7 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
28 Jun 21 Cheshire MD Common Stock Conversion Aquire C No No 0 1,046,757 0 1,980,091
28 Jun 21 Cheshire MD Common Stock Conversion Aquire C No No 0 933,334 0 933,334
28 Jun 21 Cheshire MD Series C Preferred Stock Common Stock Conversion Dispose C No No 0 1,004,887 0 0
28 Jun 21 Cheshire MD Series B-2 Preferred Stock Common Stock Conversion Dispose C No No 0 933,334 0 0
23 Jun 21 Cheshire MD Series C Preferred Stock Common Stock Aquire X No No 0 956,887 0 1,004,887
23 Jun 21 Cheshire MD Convertible Promissory Note Series C Preferred Stock Dispose X No No 7.5 - 7.18M 0
23 Jun 21 Cheshire MD Series C Preferred Stock Common Stock Sell Dispose S No No 0 192,000 0 48,000
23 Jun 21 Cheshire MD Series C Preferred Stock Common Stock Aquire X No No 0 240,000 0 240,000
23 Jun 21 Cheshire MD Warrants Series C Preferred Stock Dispose X No No 7.5 240,000 1.8M 0
22 Jun 21 Yale Phyllis R Common Stock Sell Dispose S No No 124.3266 5,048 627.6K 9,546

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

87.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 475 513 -7.4%
Opened positions 47 91 -48.4%
Closed positions 85 49 +73.5%
Increased positions 126 129 -2.3%
Reduced positions 218 221 -1.4%
13F shares
Current Prev Q Change
Total value 11.23B 13.18B -14.8%
Total shares 93.35M 97.99M -4.7%
Total puts 285.2K 431K -33.8%
Total calls 426.5K 2.14M -80.0%
Total put/call ratio 0.7 0.2 +231.5%
Largest owners
Shares Value Change
BRK.A Berkshire Hathaway 36.1M $3.89B 0.0%
Vanguard 8.3M $894.84M -3.6%
BLK Blackrock 5.99M $645.54M +0.8%
STT State Street 3.37M $362.92M -6.4%
LSV Asset Management 2.33M $250.92M -2.6%
Dimensional Fund Advisors 2.27M $244.58M -7.7%
BK Bank Of New York Mellon 1.93M $207.99M -1.6%
IVZ Invesco 1.83M $197.6M +16.6%
Geode Capital Management 1.41M $151.56M -0.6%
Gates Capital Management 1.4M $151.18M +26.3%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -1.65M EXIT
Par Capital Management 0 -1.22M EXIT
Citadel Advisors 452.66K +452.66K NEW
Veredus Asset Management 408.32K +408.32K NEW
AMP Ameriprise Financial 79.73K -399.3K -83.4%
JHG Janus Henderson 510.77K +375K +276.2%
Vanguard 8.3M -308.7K -3.6%
Gates Capital Management 1.4M +292.44K +26.3%
Glenview Capital Management 426.26K +285.64K +203.1%
IVZ Invesco 1.83M +260.96K +16.6%

Financial report summary

?
Competition
FMCFibroGenAmerican Renal Associates
Risks
  • Risks Related to the Operation of our Business
  • We face various risks related to the dynamic and evolving novel coronavirus pandemic, any of which may have a material adverse impact on us.
  • Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements, could have a material adverse effect on our business, results of operations, financial condition and cash flows, could materially harm our stock price, and in some circumstances, could materially harm our reputation.
  • Changes in federal and state healthcare legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches or suffer losses to our data and information technology assets, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.
  • We continuously have ongoing negotiations with commercial payors, and if the average rates that commercial payors pay us decline significantly, if patients in commercial plans are subject to restriction in plan designs or if we are unable to maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits, it would have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If the number or percentage of patients with higher-paying commercial insurance declines, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.
  • Changes in the structure of and payment rates under the Medicare ESRD program could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Changes in clinical practices, payment rates or regulations impacting pharmaceuticals could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients.
  • Changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and physicians willing to serve as medical directors, it could materially adversely affect our business, results of operations, financial condition and cash flows.
  • We may engage in acquisitions, mergers, joint ventures or dispositions, which may materially affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and, under certain circumstances, could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
  • If certain of our suppliers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Expansion of our operations to and offering our services in markets outside of the U.S. subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.
  • If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
  • Our ancillary services and strategic initiatives, including, without limitation, our international operations, that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one
  • or more of these activities is unsuccessful, our business, results of operations, financial condition and cash flows may be negatively impacted and we may have to write off our investment and incur other exit costs.
  • If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to law, rule or regulation, new competition, a perceived decrease in the quality of service levels at our centers or other reasons, it would have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If our labor costs continue to rise, including due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives impose additional requirements or limitations on our operations or profitability; or, if we are unable to attract and retain key leadership talent, we may experience disruptions in our business operations and increases in operating expenses, among other things, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Our business is labor intensive and could be materially adversely affected if we are unable to attract and retain employees or if union organizing activities or legislative or other changes result in significant increases in our operating costs or decreases in productivity.
  • Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems could materially adversely affect our business, results of operations, financial condition and cash flows.
  • The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control.
  • We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
  • We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition, cash flows and could materially harm our reputation.
  • If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price.
  • Deterioration in economic conditions, disruptions in the financial markets or the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law may deter changes of control and may make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: advance, CFO, classification, congressional, coupon, diem, disproportionately, dose, encounter, ESKD, HB, headcount, hypoxia, inducible, inflation, largely, light, missed, older, open, peak, PPE, presidential, prevalence, prove, realigned, recast, scientific, Sequester, sponsored, storage, surge, traditional, understood, unregistered, vaccinated, vaccine, virtual, winter
Removed: accrual, acute, adequately, amend, amendment, Amortizable, analyze, analyzing, announced, appraised, arrangement, assuming, attributed, auction, authorizing, award, Baxter, booking, buyer, capitalizing, caregiving, cautionary, CDC, challenge, charge, clearing, cloud, CMS, collaborating, compare, computing, confirmed, consolidate, consolidating, constructive, contractually, controlling, Corporation, country, cover, covering, critical, Customer, death, deconsolidation, dedicated, deem, disability, discounted, distancing, distributed, division, domestic, doubtful, Dutch, earlier, effort, employ, enhanced, equal, establish, evaluate, exceed, exercise, exercised, exposed, facing, filing, Finally, FMC, framework, front, funded, German, governing, grant, great, guarantee, guaranteed, guarantor, heightened, HHS, hold, holding, home, identification, impacting, implicit, indemnification, influence, initially, intangible, investor, lapse, largest, learned, leaseback, lost, lowering, LTIP, marketability, measurement, model, modified, monitoring, nationwide, Nephrology, notice, offer, oppose, package, payout, peritoneal, personal, personnel, predetermined, preliminary, Prepare, Prevention, prospective, protect, protocol, Pte, rapidly, reassessment, reclassification, redistribution, released, remove, represented, requirement, restating, resulted, retain, retaining, retrospective, safety, SEC, setting, settled, shortage, skilled, social, Society, software, staffing, stimulating, strategy, Subtopic, telehealth, threshold, top, transition, trillion, turn, understanding, user, utilization, utilize, variety, vary, varying, wider, world